← Leaderboards
Wolfram E Samlowski
University Of Utah
$2,068,537
Attributed
$2,068,537
Total exposure
4
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $246.1K · FY2005–08$250K$187.5K$125K$62.5K$0
'05
'06
'07
'08
Funding mix
By agency
NIH$2,068,537 · 4
By mechanism
U10$1,109,579 · 1
R21$955,710 · 2
M01$3,248 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Utah
Same institution · by research overlap
- Kathleen H Mooney$23,401,107
- William L. Carroll$23,653,738
- Donald E Ayer$14,736,202
- Andrea Hope Bild$7,326,006
- Stefanie S. Jeffrey$1,387,387
Others in their field
Top investigators on “Neoplasm /Cancer Chemotherapy”
- Charles A Coltman · Southwest Oncology Group$171,655,324
- Norman Wolmark · Nsabp Foundation, Inc.$63,095,441
- Philip J Disaia · University Of California Irvine$41,530,194
- Walter J Curran · Thomas Jefferson University$37,520,030
- Samuel A Wells · Duke University$32,148,803
- Gregory H Reaman · National Childhood Cancer Foundation$19,436,422
Research focus
Neoplasm /Cancer ChemotherapyNeoplasm /Cancer ImmunotherapyCombination Cancer TherapyClinical ResearchCombination ChemotherapyHuman Therapy EvaluationMelanomaHuman SubjectClinical Trial Phase IDrug Screening /EvaluationMetastasisDosageInterleukin 2AcetylcysteineDrug Adverse EffectIntravenous AdministrationRenal Cell CarcinomaDrug ResistanceBone Marrow TransplantationCancer Registry /ResourceCancer PreventionAntineoplasticsFemale Reproductive System NeoplasmCancer Information System
Grant awards (14)
Epigenetic Potentiation of Interferon using Decitabine$226,328
R21 · FY2008 · CA · contact PI
Epigenetic Potentiation of Interferon using Decitabine$243,677
R21 · FY2007 · CA · contact PI
Phase I trial of PHP with high-dose IL-2$194,637
R21 · FY2006 · CA · contact PI
Phase I trial of PHP with high-dose IL-2$45,000
R21 · FY2006 · CA · contact PI
Phase I trial of PHP with high-dose IL-2$246,068
R21 · FY2005 · CA
SOUTHWEST ONCOLOGY GROUP (UTAH)$283,047
U10 · FY2003 · CA
SOUTHWEST ONCOLOGY GROUP (UTAH)$283,047
U10 · FY2002 · CA
TOXICITY OF CONTINUOUS INFUSION N ACETYL CYSTEINE WITH HIGH DOSE IL2$0
M01 · FY2002 · RR
SOUTHWEST ONCOLOGY GROUP (UTAH)$275,434
U10 · FY2001 · CA
TOXICITY OF CONTINUOUS INFUSION N ACETYL CYSTEINE WITH HIGH DOSE IL2$1,624
M01 · FY2001 · RR
TOXICITY OF CONTINUOUS INFUSION N ACETYL CYSTEINE WITH HIGH DOSE IL2$0
M01 · FY2001 · RR
TOXICITY OF CONTINUOUS INFUSION N ACETYL CYSTEINE WITH HIGH DOSE IL2$0
M01 · FY2001 · RR
SOUTHWEST ONCOLOGY GROUP (UTAH)$268,051
U10 · FY2000 · CA
TOXICITY OF CONTINUOUS INFUSION N ACETYL CYSTEINE WITH HIGH DOSE IL2$1,624
M01 · FY2000 · RR